Linaprazan

Cat. No.: HY-100412
CAS No.: 248919-64-4
Molecular Formula: C₂₁H₂₆N₄O₂
Molecular Weight: 366.46
Target: Proton Pump
Pathway: Membrane Transporter/Ion Channel
Storage:
- Powder: -20°C for 3 years, 4°C for 2 years
- In solvent: -80°C for 6 months, -20°C for 1 month

Solvent & Solubility

In Vitro: DMSO: ≥ 35 mg/mL (95.51 mM)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.7288 mL</td>
<td>13.6441 mL</td>
<td>27.2881 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5458 mL</td>
<td>2.7288 mL</td>
<td>5.4576 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2729 mL</td>
<td>1.3644 mL</td>
<td>2.7288 mL</td>
<td></td>
</tr>
</tbody>
</table>

*“≥” means soluble, but saturation unknown.

Preparing Stock Solutions

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description: AZD0865 inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC₅₀: 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na+,K+-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H+,K+-ATPase. In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of AZD0865 would translate to a healing rate of 89% at 4 weeks.

REFERENCES

